Daiichi Sankyo
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Daiichi Sankyo sits in the top decile of US sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count).
Daiichi Sankyo: 236 sponsored US clinical trials, 29 recruiting.
Daiichi Sankyo sponsors 236 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 167 completed. 71 of these trials are in Phase 3-4 (later-stage) and 153 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 7 trials.
Top-decile sponsor footprint
Daiichi Sankyo ranks in the top decile of sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 189 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
236 total, page 4 of 5
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
NCT01149720
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
NCT01124630
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
NCT01101334
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
NCT01055067
Prasugrel/Clopidogrel Maintenance Dose Washout Study
NCT01014624
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01075048
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
NCT01049893
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
NCT00989261
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
NCT00945191
Safety Study of PLX108-01 in Patients With Solid Tumors
NCT01004861
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
NCT00986154
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
NCT00967616
Olmesartan Comparison to Losartan in Hypertensive Subjects
NCT00949884
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
NCT00789750
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
NCT00881569
Welchol as Monotherapy for Type 2 Diabetes Mellitus
NCT00789737
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
NCT00806286
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
NCT00781391
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
NCT00791258
Effects of Multiple Doses of CS-8080 in Healthy Volunteers
NCT00796575
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
NCT00717769
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
NCT00698828
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
NCT00649389
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
NCT00654745
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
NCT00616733
Effects of CS-8080 in Healthy Volunteers
NCT00613431
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
NCT00603941
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00571519
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
NCT00570739
Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
NCT00527514
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
NCT00521404
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
NCT00623363
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
NCT00504556
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
NCT00484419
Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00484198
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
NCT00430638
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
NCT00412932
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
NCT00408434
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
NCT00403481
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
NCT00398216
Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
NCT00361153
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
NCT00290940
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
NCT00145574
Olmesartan Pediatric Pharmacokinetic (PK) Study
NCT00151814
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
NCT00185120
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
NCT00147745
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
NCT00185133
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
NCT00151775
Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol
NCT00185107
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 90 |
| Phase 2 | 63 |
| Phase 3 | 50 |
| Phase 4 | 21 |
What is open in the Daiichi Sankyo pipeline
29 recruiting of 236 indexed (12% open); 167 completed (71%).
Phase mix: 71 late (III/IV) vs 153 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Daiichi Sankyo: open-pipeline peers nationwide
Peers matched on 236 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Daiichi Sankyo sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 236 trials (± recruiting share)
- Loma Linda University · 237 trials · 15% recruiting
- Henry Ford Health System · 234 trials · 18% recruiting
- Incyte Corporation · 239 trials · 15% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 12% open enrollment (± trial volume)
- University of Iowa · 12% recruiting · 228 trials
- Augusta University · 12% recruiting · 106 trials
- National Institute of Mental Health (NIMH) · 12% recruiting · 343 trials
- National Heart, Lung, and Blood Institute (NHLBI) · 12% recruiting · 501 trials
Related
What to do with this Daiichi Sankyo page
236 registered trials is a research-attention snapshot, not an endorsement of Daiichi Sankyo or any single study.
- 29 of Daiichi Sankyo's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition Daiichi Sankyo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Daiichi Sankyo pipeline card: 236 registered trials from official public datasets.Report a data error.